Ethics and the Pharmaceutical Industry

Michael A. Santoro; Thomas M. Gorrie

doi:10.1017/CBO9780511610769

Search within full text

Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing.

'… Michael Santoro and Thomas Gorrie have compiled a series of essays that provide a fair, balanced and insightful examination of an increasingly troubled relationship between the pharmaceutical industry and society.'

Source: Journal of the American Medical Association

- Aa Reduce text
- Aa Enlarge text

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

Page 1 of 2

First
« Prev
1
2
Next »
Last

Contents

Frontmatter
pp i-iv
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Contents
pp v-viii
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Tables
pp ix-x
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Figures
pp xi-xii
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

About the Editors
pp xiii-xiv
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Contributors
pp xv-xxvi
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Preface
pp xxvii-xxx
- By Michael A. Santaro, Rutgers University, New Jersey, Thomas M. Gorrie, Johnson and Johnson
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Acknowledgments
pp xxxi-xxxii
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Foreword
pp xxxiii-xxxiv
- By Delon Human, M.D., Secretary-General and CEO, The World Medical Association (WMA)
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
pp 1-6
- By Michael A. Santaro, Rutgers University, New Jersey
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

PART I - PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
pp 7-8
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Introduction to Part I
pp 9-20
- By Michael A. Santaro, Rutgers University, New Jersey
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

1 - Drug Research: Between Ethical Demands and Economic Constraints
pp 21-36
- By Jürgen Drews, Chairman of the Board, Genaissance Pharm. Inc.; Director and Partner, Bear Stearns Health Innoventure Fund LLC
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

2 - Emerging International Norms for Clinical Testing: Good Clinical Trial Practice
pp 37-47
- By Juhana E. Idänpään-Heikkilä, Secretary-General of the Council for International Organizations of Medical Sciences (CIOMS), World Health Organization (WHO) in Geneva, Sev Fluss, Senior Adviser, Council for International Organizations of Medical Sciences in Geneva
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

3 - The Regulatory and Ethical Challenges of Pediatric Research
pp 48-67
- By M. Dianne Murphy, Director of the Office of Pediatric Therapeutics, FDA's Office of the Commissioner, Sara F. Goldkind, Bioethicist, Office of Pediatric Therapeutics within the Office of the Commissioner of the Food and Drug Administration
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

4 - Including Children in Research: Participation or Exploitation?
pp 68-79
- By Robert M. Nelson, Associate Professor of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

5 - Racial and Ethnic Inclusiveness in Clinical Trials
pp 80-96
- By Valentine J. Burroughs, Chief Medical Officer and Chairman of the Department of Medicine, North General Hospital in New York City
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

6 - The Rights of Patients to Participate in Clinical Research
pp 97-108
- By Glenna M. Crooks, President & CEO, Strategic Health Policy International, Inc.
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

7 - How Should Government Regulate Stem-Cell Research? Views from a Scientist-Legislator
pp 109-124
- By Rush Holt, Representative for the 12th district of New Jersey, U.S. House of Representatives
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

PART II - MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
pp 125-126
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Introduction to Part II
pp 127-135
- By Michael A. Santaro, Rutgers University, New Jersey
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

8 - Ethics and Prescribing: The Clinician's Perspective
pp 136-152
- By Charles L. Bardes, Professor of Clinical Medicine and Associate Dean, Weill Medical College of Cornell University
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

9 - The Regulation of Prescription Drug Promotion
pp 153-168
- By Thomas Abrams, Director, Division of Drug Marketing, Advertising, and Communications, U.S. Food and Drug Administration
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

10 - Direct-to-Consumer Advertising of Prescription Drugs: A Policy Dilemma
pp 169-183
- By Meredith B. Rosenthal, Assistant Professor of Health Economics and Policy in the Department of Health Policy and Management, Harvard University, Julie M. Donohue, Assistant Professor in the Department of Health Policy & Management in the Graduate School of Public Health, University of Pittsburgh
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

11 - Off-Label Communications and Prescription Drugs
pp 184-195
- By Scott D. Danzis, Associate, Law firm of Covington & Burling in Washington, D.C.
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

12 - The Need for Better Health Information: Advancing the Informed Patient in Europe
pp 196-205
- By Don E. Detmer, President and CEO, American Medical Informatics Association; Professor Emeritus and Professor of Medical Education, Department of Health Sciences at the University of Virginia; Senior Associate, Judge Business School, University of Cambridge, Peter Singleton, Senior Associate, Judge Institute, University of Cambridge; Principal Research Fellow, Centre for Health Informatics and Multiprofessional Education (CHIME), University College London; Founder and Director, Cambridge Health Informatics Limited (CHIL), Scott C. Ratzan, Vice President, Government Affairs, Europe, for Johnson & Johnson
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

13 - Who Should Get Access to Which Drugs? An Ethical Template for Pharmacy Benefits
pp 206-224
- By Norman Daniels, Mary B. Saltonstall Professor and Professor of Ethics and Population Health, Harvard School of Public Health, James E. Sabin, Clinical Professor of Psychiatry, Harvard Medical School; Director of Teaching, DACP; Director, Harvard Pilgrim Health Care Ethics Program; Director, Center for Ethics in Managed Care, J. Russell Teagarden, Vice President of Clinical Practices and Therapeutics, Medco Health Solutions, Inc.
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

14 - The Application of Cost-Effectiveness and Cost–Benefit Analysis to Pharmaceuticals
pp 225-248
- By Joel W. Hay, Associate Professor in the Department of Pharmaceutical Economics and Policy in the School of Pharmacy and the Department of Economics, University of Southern California
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

PART III - PATENTS, PRICING, AND EQUAL ACCESS
pp 249-250
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Introduction to Part III
pp 251-259
- By Michael A. Santaro, Rutgers University, New Jersey
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation

Page 1 of 2

First
« Prev
1
2
Next »
Last

Metrics

Total number of HTML views: 0

Total number of PDF views: 0 *

Loading metrics...

Total views: 0 *

Loading metrics...

* Views captured on Cambridge Core between #date#. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Ethics and the Pharmaceutical Industry

This Book has been cited by the following publications. This list is generated based on data provided by Crossref.

Book description

Reviews

Refine List

Actions for selected content:

Contents

Frontmatter
pp i-iv

Contents
pp v-viii

Tables
pp ix-x

Figures
pp xi-xii

About the Editors
pp xiii-xiv

Contributors
pp xv-xxvi

Preface
pp xxvii-xxx

Acknowledgments
pp xxxi-xxxii

Foreword
pp xxxiii-xxxiv

Introduction: Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry
pp 1-6

PART I - PROFITS, PATIENTS' RIGHTS, AND SCIENTIFIC PROGRESS: THE ETHICS OF CLINICAL RESEARCH CONDUCTED IN PRIVATE ENTERPRISES
pp 7-8

Introduction to Part I
pp 9-20

1 - Drug Research: Between Ethical Demands and Economic Constraints
pp 21-36

2 - Emerging International Norms for Clinical Testing: Good Clinical Trial Practice
pp 37-47

3 - The Regulatory and Ethical Challenges of Pediatric Research
pp 48-67

4 - Including Children in Research: Participation or Exploitation?
pp 68-79

5 - Racial and Ethnic Inclusiveness in Clinical Trials
pp 80-96

6 - The Rights of Patients to Participate in Clinical Research
pp 97-108

7 - How Should Government Regulate Stem-Cell Research? Views from a Scientist-Legislator
pp 109-124

PART II - MARKETING AND THE EFFICIENT UTILIZATION OF HEALTHCARE RESOURCES: ETHICAL AND PUBLIC POLICY CHALLENGES
pp 125-126

Introduction to Part II
pp 127-135

8 - Ethics and Prescribing: The Clinician's Perspective
pp 136-152

9 - The Regulation of Prescription Drug Promotion
pp 153-168

10 - Direct-to-Consumer Advertising of Prescription Drugs: A Policy Dilemma
pp 169-183

11 - Off-Label Communications and Prescription Drugs
pp 184-195

12 - The Need for Better Health Information: Advancing the Informed Patient in Europe
pp 196-205

13 - Who Should Get Access to Which Drugs? An Ethical Template for Pharmacy Benefits
pp 206-224

14 - The Application of Cost-Effectiveness and Cost–Benefit Analysis to Pharmaceuticals
pp 225-248

PART III - PATENTS, PRICING, AND EQUAL ACCESS
pp 249-250

Introduction to Part III
pp 251-259

Metrics

Full text views

Book summary page views

Ethics and the Pharmaceutical Industry

Book description

Reviews

Refine List

Actions for selected content:

Save Search

Contents

Metrics

Full text views

Book summary page views